Rapport Therapeutics, Inc. RAPP 深 沪
等待开盘 12-16 09:30:00 美东时间
29.60
-0.670
-2.21%
华盛通- 最 高30.86
- 今 开30.67
- 成交量 26.00万股
- 最 低 29.545
- 昨 收 30.27
- 总市值 13.65亿
- 52周最高 42.2685
- 市盈率 静 --
- 换手率 0.56%
- 52周最低 6.43
- 委 比 67.91%
- 总股本 4611.31万
- 历史最高 42.2685
- 量 比 0.84
- 振 幅 4.34%
- 历史最低 6.43
- 每 手 1
- 风险率 6.77%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 花旗上调苹果目标价升至330美元；GPCR、KYMR、MAMA、TERN、WVE等获多家机构上调目标价
今日重点评级关注：Chardan Capital：维持Senti Biosciences"买入"评级，目标价从12美元升至13美元；Guggenheim：维持Praxis Precision Medicine"买入"评级，目标价从540美元升至760美元
12-10 10:33
Rapport Therapeutics Announces New Data And Post Hoc Analysis On Clinical And Patient Reported Benefits Of RAP-219 In Drug-Resistant FOS, Alongside Topline Efficacy And Safety Data From Phase 2a FOS Trial
Post-hoc analysis of RAP-219 Phase 2a data showed early onset of action and consistency of median response over the entire treatment period, along with consistent efficacy data regardless of patients' disease
12-05 22:03
美股大行评级 | 高盛上调百度、美敦力、晶科能源等多只个股目标价；家得宝遭9家机构下调目标价；
今日重点评级关注：富国银行：维持Annexon"超配"评级，目标价从14美元升至27美元；瑞穗：上调Relmada Therapeutics评级至"跑赢大市"，目标价从1美元升至10美元
11-20 10:28
BTIG Initiates Coverage On Rapport Therapeutics with Buy Rating, Announces Price Target of $47
BTIG analyst Kambiz Yazdi initiates coverage on Rapport Therapeutics (NASDAQ:RAPP) with a Buy rating and announces Price Target of $47.
11-19 18:12
美股大行评级 | 潜在涨幅1307.13%！HC Wainwright & Co.：Adicet Bio获机构升目标价至9美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从4美元升至9美元；Citizens: 维持Rapport Therapeutics"跑赢大市"评级，目标价从77美元升至80美元
11-10 17:17
美股大行评级 | 潜在涨幅1307.13%！HC Wainwright & Co.：Adicet Bio获机构升目标价至9美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Adicet Bio"买入"评级，目标价从4美元升至9美元；Citizens: 维持Rapport Therapeutics"跑赢大市"评级，目标价从77美元升至80美元
11-10 10:22
Citizens Maintains Market Outperform on Rapport Therapeutics, Raises Price Target to $80
Citizens analyst Jason N. Butler maintains Rapport Therapeutics (NASDAQ:RAPP) with a Market Outperform and raises the price target from $77 to $80.
11-07 22:21
Rapport Therapeutics Q3 EPS $(0.71) Beats $(0.77) Estimate
Rapport Therapeutics (NASDAQ:RAPP) reported quarterly losses of $(0.71) per share which beat the analyst consensus estimate of $(0.77) by 7.19 percent. This is a 42 percent decrease over losses of $(0.50) per share from
11-06 20:11
美股大行评级 | Arete Research上调百度"买入"评级，目标价143美元；瑞银上调蔚来"买入"评级，目标价升至8.5美元
今日重点评级关注：HC Wainwright & Co.：维持Orion Energy Sys"买入"评级，目标价从2美元升至20美元；高盛：维持Amylyx Pharmaceuticals"买入"评级，目标价从10美元升至20美元
09-17 10:15
Rapport assigned a new Buy at Truist on lead program
Rapport Therapeutics (NASDAQ:RAPP) traded higher on Tuesday after Truist launched its coverage with a Buy recommendation and a $44 price target, citing the neuro drug developer’s lead candidate RAP-21...
09-17 02:28
